重大事件
即時報告
8-K
2026-07-02
Seer 創辦人兼CEO提出每股2.45美元現金加CVR非約束性收購建議
AI 繁中摘要
Seer（納斯達克：SEER）公佈收到創辦人兼行政總裁 Omid Farokhzad 醫生提出的非約束性收購建議，擬以每股 2.45 美元現金及兩項獨立或有價值權（CVR）收購公司全部已發行 A 類普通股 🧾。董事會將成立全部由獨立董事組成的特別委員會，並聘請獨立財務及法律顧問評估該建議及其他可行方案，以決定最符合公司及股東利益的行動。目前股東無需採取任何行動 📌。是次收購建議屬初步及非約束性，最終條款尚待協商。投資者宜留意特別委員會後續公告及潛在股價波動 ⚠️。
展開英文正文
EX-99.1 2 ck0001726445-ex99_1.htm EX-99.1 EX-99.1 Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D. No Stockholder Action Required at This Time REDWOOD CITY, Calif. – July 2, 2026 – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has received an unsolicited, non-binding proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights (the “Proposal”). The full text of the letter received from Dr. Farokhzad outlining the Proposal will be included on a Form 8-K filing made by Seer. Seer’s Board of Directors will establish a Special Committee consisting solely of independent directors. The Special Committee will evaluate the Proposal and other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and its stockholders. The Special Committee will retain independent financial and legal advisors to assist it with its work. No stockholder action is required at this time. Perella Weinberg Partners LP is serving as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio. For more information, please email us at [email protected]. Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions to be taken by the Board and the Special Committee. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Media Contact: Patrick Schmidt [email protected] Joele Frank, Wilkinson Brimmer Katcher Eric Brielmann / Joseph Sala (212) 355-4449 Investor Contact: Marissa Bych [email protected]